Behcets Disease Therapeutics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, UK, Germany, Japan - Size and Forecast 2024-2028

Behcet's Disease Therapeutics Market 2024-2028

The Global Behcet's Disease Therapeutics Market size is estimated to grow by USD 437.57 million at a CAGR of 6.82% between 2023 and 2028. 

There has been increasing research funding for rare diseases over the years. In addition, the global Behcets disease therapeutics market has only two approved drugs for the treatment of the condition. Even though the condition is rare, its increasing prevalence and the lack of approved therapies have resulted in an unmet need for treatment using drugs available on the market. Moreover, this has resulted in intense R&D of novel therapies by vendors and research institutes for the development of treatment for Behcet's disease. Hence, such factors are positively impacting the market.

Technavio has segmented the market into Route Of Administration, Product, and Geography

• The route of administration segment is classified into oral and injectable
• The product segment is classified into small molecules and biologics
• The geography segment includes key regions such as North America, Europe, Asia, and Rest of the World (ROW)

It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historical data from 2018 - 2022, besides analyzing the current market scenario.

What will be the Size of the Behcet's Disease Therapeutics Market During the Forecast Period?

To learn more about this report, Download Report Sample

Behcet's Disease Therapeutics Market Segmentation by Route Of Administration, Product and Geography Analysis

Route Of Administration Analysis

Oral

The oral segment is estimated to witness significant growth during the forecast period. Minimizing inflammation is the main goal of most Behcet's disease treatments. In addition, to assist in reducing inflammation, a doctor may prescribe a combination of immune-suppressing drugs and anti-inflammatory drugs called corticosteroids. Furthermore, immunosuppressants such as tacrolimus, ciclosporin, and azathioprine are used to treat Behcet's disease.

Get a glance at the market contribution of various segments Download PDF Sample

The oral segment was the largest segment and was valued at USD 549.12 million in 2018. Moreover, these medications come in the form of tablets, capsules, or injections. In addition, the anti-inflammatory drug colchicine, which is frequently prescribed for gout, might potentially be helpful. Furthermore, corticosteroid medicines are applied directly to the skin and genital sores to reduce inflammation and pain. As most of the Behcets disease drugs are orally consumed, it is expected to fuel the growth of this segment which in turn will drive the market growth during the forecast period.

Product Analysis

Small molecules

The small molecules segment comprises drugs that are produced synthetically and are highly efficient in treating various indications. In addition, these types of drugs are known to enter cells easily due to their low molecular weight, which is less than 900 Daltons. Moreover, after reaching the target site, in a particular cell, small molecules kill the affected cells in the body. In addition, small molecules have become a popular treatment option in the global Behcets disease therapeutics market due to their heavy acceptance and strong efficacy. Furthermore, despite the increasing advances in research of various biologics, including targeted therapies, the cost-effectiveness and strong penetration of these small molecule-based drugs help the segment remain the largest segment of the global Behcets disease therapeutics market during the forecast period.

Biologics

Biologics segments are manufactured using a living system, such as microorganisms, plant, or animal cells, or cellular products such as hormones and enzymes. In addition, most of the biologics are very large, complex molecules or mixtures of molecules. Moreover, most of them are manufactured using recombinant deoxyribose nucleic acid (DNA) technology. In addition, a small molecule drug is typically manufactured through chemical synthesis. Furthermore, small molecules have definite chemical structures, and a finished product can generally be analyzed to find all its several components. In addition, due to the strong stability of biologics, the treatment of Behcet's disease is often very effective and has minimal side effects, as these biologics have proven their efficacy and safety profile in the treatment of other autoimmune diseases. Hence, it is expected to fuel the growth of this segment which in turn will drive the market growth during the forecast period.

Regional Analysis

For more insights about the market share of various regions Download PDF Sample now!

North America is estimated to contribute 43% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. Factors such as the heavy use of off-label drugs and the increasing dominance of biologics in the region for the treatment of the indication is fuelling the market growth in North America. In addition, the region is heavily dominated by the presence of various biologics such as TNF inhibitors, interleukin inhibitors, and immunosuppressants that are used as off-label and small molecule targeted therapies such as PDE4 inhibitors that are approved for the treatment of the condition. Moreover, despite the high cost of treatment, the market is expected to witness an increase in the adoption of drugs, owing to the availability of various patient-assistance programs and reimbursement programs for rare diseases offered by companies and government bodies in the US and Canada. Hence, such factors are driving the market growth in North America during the forecast period.

Buy Full Report Now

Key Behcet's Disease Therapeutics Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 10 market companies, including:

AbbVie Inc: The company offers Behcet's disease therapeutics using a drug named HUMIRA which is given by injection under the skin and can be used alone, with methotrexate, or with certain other medicines. 

• Amgen Inc
• F. Hoffmann La Roche Ltd.
• Johnson and Johnson
• Mitsubishi Chemical Group Corp.
• Novartis AG
• Pfizer Inc.
• Takeda Pharmaceutical Co. Ltd.
• Viatris Inc.
• Xoma Corp.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Behcet's Disease Therapeutics Market: Key Drivers, Trends, Challenges, and Customer Landscape

There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. 

Key Behcet's Disease Therapeutics Market Drivers

One of the key factors driving the Behcet's disease therapeutics market growth is the special drug designations. Due to the proven efficacy, the drugs that treat Behcet's disease and the therapeutic candidates that are currently under development for the treatment of the condition have been awarded special drug designations by regulatory bodies. In addition, many such drugs received designations such as the breakthrough drug designation and the orphan drug designation from regulatory bodies such as the US FDA and the EMA.

Moreover, these designations help to enhance research and enable drugs to reach the market at the earliest. In addition, the companies that receive the orphan drug designation for their drugs also get certain benefits. For example, sponsors of drugs with the orphan drug designation receive the benefit of various development incentives, which include tax credits of up to 50% on the costs of clinical trials. Hence, such factors are driving the market growth during the forecast period.

Significant Behcet's Disease Therapeutics Market Trends

A key factor shaping Behcet's disease therapeutics market growth is the increasing awareness about rare diseases. The growing awareness about rare diseases, including Behcet's disease, is important, as one in 20 people live with a rare disease at some point in their lives. In addition, there is no complete cure for the majority of rare diseases, and many of these diseases remain undiagnosed. Therefore, several organizations are introducing awareness programs to spread awareness about rare diseases including Behcet's disease.

For example, the American Behcet's Disease Association has advocates who spread awareness about the disease through online articles, radio broadcasts, and public events such as roadside shows. In addition, the association is also helping to spread awareness about the disease through some video clips, in which the advocates of the association, some American patients, and medical advisory board members of the association have a major role play. Hence, such factors are driving the market growth during the forecast period.

Major Behcet's Disease Therapeutics Market Challenges

Adverse effects of small molecule-based drugs are one of the key challenges hindering Behcet's disease therapeutics market growth. Even though the treatment landscape of autoimmune disorders is developing signficantly, the number of treatment options for Behcet's disease is limited, as it is a rare disease. In addition, the treatment landscape of Behcet's disease is dominated by small molecule-based drugs.

However, these drugs exhibit a range of adverse effects, including fatigue, muscle cramps, nausea, vomiting, and diarrhea. In addition, they are also associated with some rare events, such as low blood count, edema, congestive heart failure, and severe liver problems. Furthermore, a combination of small molecule-based drugs also leads to myelosuppression. Hence, such factors are negatively impacting the market. Therefore, it is expected to hinder the market growth during the forecast period.

Buy Now Full Report

Key Behcet's Disease Therapeutics Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Behcet's Disease Therapeutics Market Customer Landscape

Segment Overview

The Behcet's disease therapeutics market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028. 

• Route Of Administration Outlook
  • Oral
  • Injectable
• Product Outlook
  • Small molecules
  • Biologics
• Geography Outlook
  • North America
    • The U.S.
    • Canada
  • Europe
    • The U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • Rest of the World (ROW)
    • Australia
    • Argentina
    • Brazil

Behcet's Disease Therapeutics Market Scope
Report Coverage	Details
Page number	149
Base year	2023
Historic period	2018-2022
Forecast period	2024-2028
Growth momentum & CAGR	Accelerate at a CAGR of 6.82%
Market Growth 2024-2028	USD 437.57 million
Market structure	Concentrated
YoY growth 2023-2024(%)	5.7
Regional analysis	North America, Europe, Asia, and the Rest of the World (ROW)
Performing market contribution	North America at 43%
Key countries	US, Canada, UK, Germany, and Japan
Competitive landscape	Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks
Key companies profiled	AbbVie Inc., Amgen Inc., F. Hoffmann La Roche Ltd., Johnson and Johnson, Mitsubishi Chemical Group Corp., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd., Viatris Inc., and Xoma Corp.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Behcet's Disease Therapeutics Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the Behcet's disease therapeutics market between 2024 and 2028
• Precise estimation of the behcet's disease therapeutics market size and its contribution of the market in focus on the parent market
• Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
• Companies landscape comparing criticality of inputs and factors of differentiation
• Exclusive Matrix on companies position and classification
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the market across North America, Europe, Asia, and the Rest of the World (ROW)
• A thorough analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of behcet's disease therapeutics market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch